GlassScriptPhysician profile
Rachel Bijou
NPI 1225115082
$4,497.82
in general payments reported to CMS, 2019-2025
23 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $187 · 2021: $183 · 2022: $396 · 2023: $591 · 2024: $1,115 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,087.87 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Thoratec Heartmate 3 |
| Novartis Pharmaceuticals Corporation | $958.23 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $375.51 | 2019-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $343.01 | 2023-2025 | Verquvo |
| Impulse Dynamics (USA) INC. | $300.47 | 2022-2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.78 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $233.66 | 2020-2025 | Wainua, Farxiga, Lokelma |
| Daiichi Sankyo INC. | $191.81 | 2019-2024 | Injectafer |
| Abiomed | $135.77 | 2024 | Impella |
| Scpharmaceuticals INC. | $107.88 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $90.04 | 2019-2020 | |
| Akcea Therapeutics, INC. | $71.42 | 2019 | |
| Amgen INC. | $55.59 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.93 | 2020-2024 | Lifevest |
| Bridgebio Pharma, INC. | $49.93 | 2025 | Attruby |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.91 | 2019-2025 | Camzyos |
| Lundbeck LLC | $25.98 | 2019 | |
| Amarin Pharma, INC. | $21.20 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $21.15 | 2023 | Arcalyst |
| Veloxis Pharmaceuticals, INC. | $20.13 | 2025 | Envarsus |
| Pfizer INC. | $17.50 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $15.45 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $13.60 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bijou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.